Michael Atkins

(PQ #8) Biomarkers of Efficacy and Adverse Events Due to Treatment with Immune Checkpoint Inhibitors

National Cancer Institute · R01

PI · $2.6M · Georgetown University

Dana-Farber/Harvard Cancer Center

National Cancer Institute · P30

Project lead · $443.4K · Dana-Farber Cancer Inst

DF/HCC Kidney Cancer SPORE

National Cancer Institute · P50

Contact PI · $18.5M · Beth Israel Deaconess Medical Center

Eastern Cooperative Oncology Group

National Cancer Institute · U10

Contact PI · $1.3M · Beth Israel Deaconess Medical Center

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Principal investigator · Suspended · Phase 2

Michael B. Atkins, MD

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Principal investigator · Terminated · Phase 2

Melanoma Research Foundation Breakthrough Consortium

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

Principal investigator · Terminated · Phase 2

Georgetown University

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Principal investigator · Completed · Phase 1

National Cancer Institute (NCI)